Shares of Johnson Matthey PLC (LON:JMAT – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is GBX 2,283.33.
A number of equities analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,330 price objective on shares of Johnson Matthey in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 2,400 price target on shares of Johnson Matthey in a report on Monday, July 6th.
Get Our Latest Stock Report on JMAT
Johnson Matthey Stock Down 2.4%
Shares of JMAT stock opened at GBX 2,418 on Tuesday. The company has a current ratio of 1.56, a quick ratio of 0.76 and a debt-to-equity ratio of 69.69. Johnson Matthey has a 12 month low of GBX 2,192 and a 12 month high of GBX 3,245.33. The stock has a market cap of £3.04 billion, a P/E ratio of -31.70, a P/E/G ratio of 49,242.50 and a beta of 0.93. The company has a 50 day simple moving average of GBX 2,326.78 and a two-hundred day simple moving average of GBX 2,141.54.
Insider Buying and Selling
In other news, insider Liam Condon bought 10,951 shares of the stock in a transaction on Friday, September 11th. The stock was acquired at an average cost of GBX 2,306 per share, for a total transaction of £252,530.06. Also, insider Richard Pike acquired 17,635 shares of Johnson Matthey stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average cost of GBX 2,248 per share, with a total value of £396,434.80. In the last ninety days, insiders bought 28,608 shares of company stock valued at $64,947,512. Company insiders own 0.77% of the company’s stock.
Johnson Matthey Company Profile
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources. Today more than 13,000 Johnson Matthey professionals collaborate with their network of customers and partners to make a real difference to the world around us.
See Also
- Five stocks we like better than Johnson Matthey
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.
